21 related articles for article (PubMed ID: 12044058)
1. Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma.
Wu YJ; Neuwelt AJ; Muldoon LL; Neuwelt EA
Anticancer Res; 2013 Jun; 33(6):2391-400. PubMed ID: 23749887
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y.
Bilir A; Erguven M; Yazihan N; Aktas E; Oktem G; Sabanci A
J Neurooncol; 2010 Dec; 100(3):385-95. PubMed ID: 20467784
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of various bioabsorbable and nonresorbable barrier membranes for guided tissue regeneration.
Kasaj A; Reichert C; Götz H; Röhrig B; Smeets R; Willershausen B
Head Face Med; 2008 Oct; 4():22. PubMed ID: 18854011
[TBL] [Abstract][Full Text] [Related]
4. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
6. S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro.
Wang Q; He Z; Gao J; Hu S; Huang M; Liu M; Zheng J; Tang H
Cancer Lett; 2008 Dec; 272(2):277-84. PubMed ID: 18762368
[TBL] [Abstract][Full Text] [Related]
7. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
8. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
9. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer.
Altinoz MA; Korkmaz R
Neoplasma; 2004; 51(4):239-47. PubMed ID: 15254653
[TBL] [Abstract][Full Text] [Related]
10. Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro.
Bilir A; Altinoz MA; Attar E; Erkan M; Aydiner A
Neoplasma; 2002; 49(1):38-42. PubMed ID: 12044058
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
